BiotechTube

Sham Injection + FAI Insert

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Posterior Uveitis

Conditions

Posterior Uveitis, Intermediate Uveitis, Panuveitis

Trial Timeline

Jun 2, 2015 → Oct 4, 2019

NCT ID
NCT02746991

About Sham Injection + FAI Insert

Sham Injection + FAI Insert is a phase 3 stage product being developed by EyePoint Pharmaceuticals for Posterior Uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02746991. Target conditions include Posterior Uveitis, Intermediate Uveitis, Panuveitis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02746991Phase 3Completed

Competing Products

10 competing products in Posterior Uveitis

See all competitors
ProductCompanyStageHype Score
Ixekizumab Prefilled SyringeEli LillyApproved
85
AdalimumabAbbVieApproved
85
Esomeprazole + PlaceboAstraZenecaApproved
85
Azithromycin ophthalmic solution, 1%MerckPhase 2
52
Sugammadex Injection [Bridion] + PlaceboMerckApproved
85
FTY720 + Oral CorticosteroidNovartisPhase 2
52
REGN7041Regeneron PharmaceuticalsPhase 1/2
40
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)BaxterPhase 2
49
ESK-001AlumisPhase 2
47
CF101 + PlaceboCan Fite BiopharmaPhase 2
44

Other Products from EyePoint Pharmaceuticals

Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)Approved
80
Dexamethasone + Prednisolone Acetate OphthalmicApproved
80
DexycuPhase 3
72
FAI insert + Sham injectionPhase 3
72
Sham Injector + FAI InsertPhase 3
72